The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00500305

Enrollment

Registered

2007-07-12

Start date

2004-04-30

Completion date

2007-03-31

Last updated

2018-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Indomethacin Therapy, Patent Ductus Arteriosus

Keywords

indomethacin therapy, patent ductus arteriosus

Brief summary

A patent ductus arteriosus (PDA) is associated with increased morbidity in premature infants. Standard indomethacin treatment is associated with intestinal and renal morbidity. B-type natriuretic peptide is elevated in significant PDAs. This study will determine whether BNP guided therapy could reduce doses of indomethacin.

Interventions

PROCEDUREWithhold standard INDO dose if BNP < 100 pg/ml

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 4 Months

Healthy volunteers

Inclusion criteria

* Infants with echocardiographically confirmed PDA * Infants determined by attending physician to require PDA closure

Exclusion criteria

* infants with congenital hearts disease * infants with creatinine value \> 2.0

Design outcomes

Primary

Measure	Time frame
Number of indomethacin doses given on study	2 days

Secondary

Measure	Time frame
rate of PDA ligation	Discharge from NICU
Rate of Chronic lung disease	36 weeks corrected gestational age

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026